Mozambique launches Brazil-funded drugs plant to battle HIV

Mozambique on Saturday launched a Brazilian funded pharmaceutical plant that will make anti-retroviral drugs to battle the HIV/AIDS scourge in the southern African country.

The factory -- built with $23 million in aid from Brazil and $4.5 million from that country's mining giant Vale -- will initially package drugs from Brazil but start producing the pills by the end of the year.

Mozambique has more than 2.5 million people living with HIV -- nearly 12 percent of the population -- but fewer than 300,000 of them now take anti-retroviral (ARV) drugs, according to the .

ARVs suppress the , reducing sickness and death rates as well as the transmission of the virus that causes AIDS.

Brazil's Vice President Michel Temer attended Saturday's launch of what is thought to be Africa's first fully public ARV factory in Matola, along with Mozambique's Industry and Commerce Minister Armando Inroga.

"As of now drugs which were manufactured in Brazil will be packaged here in Mozambique, certified and distributed to the Mozambican people," Temer said.

"There is an excellent partnership between the Brazilian and the Mozambican people and there is an absolute integration between the two countries in both public and private sectors."

In 2010 Brazil's then-president Luiz Inacio Lula da Silva visited the plant site and called it a "revolution" in Africa's fight against HIV/AIDS.

Brazil offers free ARV treatment to HIV-positive citizens, a programme that sparked controversy when it was announced in 1996 because of concerns about and violation of pharmaceutical copyright.

But it has since been praised as a model for the developing world. The World Bank estimates the free medicine saved more than half a million lives.

Mozambican technicians and other staff for the plant are now being trained, some of them in Brazil, through a partnership with the Brazilian public health institution A Fundacao Oswaldo Cruz.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

HIV+ women respond well to HPV vaccine

Apr 16, 2014

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

User comments